These three companies are doing exceptionally well thanks to the pandemic. Will they be able to sustain momentum once the madness dies down?
Novavax’s [NVAX] share price has climbed a staggering 1,969.7% so far this year as investors bet on who will be the first to develop a coronavirus vaccine.
The key variable in this race is not the phase 3 trial, but which company has enough positive data for an Emergency Use Authorization.
The dynamics are completely different for these two healthcare stocks.